A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. (Q41940144)
Jump to navigation
Jump to search
scientific article published on June 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. |
scientific article published on June 2015 |
Statements
A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies (English)
Hélène Sicard
Cécile Bonnafous
Ariane Morel
Martine Bagot
Anne Marie-Cardine
1 June 2015